References
- Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
- Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77:1081-7
- Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. Washington (DC): US Census Bureau 2014:2-6
- Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010;75:526-32
- Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6Suppl):2455-63
- Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193:1572-80
- Kim TH, Lee KS. Persistence and compliance with medication management in the treatment of overactive bladder. ICUrology 2016;57:84-93
- Kenelley MJ. A comparative review of oxybutynin chloride formulation: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 2010;12:12-19
- Maman K, Aballea S, Nazir, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-65
- Pindoria N, Malde S, Nowers J, et al. Persistence with mirabegron therapy for overactive bladder: A real life experience. Neurourology and urodynamics 2017;36:404-8
- Wagg A, Franks B, Ramos B, et al. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J 2015;9:343-50
- Nitti VW, Rovner ES, Franks B, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits 2016;8:e25-e33
- Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-93
- Cox L, Cameron AP. OnabotulinumtoxinA for the treatment of overactive bladder. Res Rep Urol 2014;6:79-89
- Ramos HL, Castellanos LT, Esparza IP, et al. Management of overactive bladder with onabotulinumtoxinA: systematic review and meta-analysis. Urology 2017;100:53-8
- Mirabegron prescribing information. Astellas Pharma, Inc. Revised June 2012
- Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
- Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
- Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
- Karsenty G, Baverstock R, Carlson K, et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract 2014;68:731-42
- Wu JM, Siddiqui NY, Amundsen CL, et al. Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence. J Urol 2009;181:2181-6
- Hepp Z, Yehoshua A, Gultyaev D, et al. Cost-effectiveness of onabotulinumtoxinA versus PTNS and SNS for the treatment of overactive bladder from the US payer perspective. Value Health 2016;19:PUK11
- Ruff L, Bagshaw E, Aracil J, et al. Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe. J Med Econ 2016;19:1107-15
- Wielage RC, Perk S, Campbell NL, et al. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. J Med Econ 2016;19:1135-43